Negev Labs is a biotech company-building platform founded in 2022 and headquartered in Fort Lee, New Jersey, dedicated to advancing neuroplastogens — non-hallucinogenic compounds that promote neuroplasticity and cellular resilience. The company operates through R&D partnerships with Hadassah Brain Labs Center for Psychedelic Research in Jerusalem, a licensing agreement with the Alexander Shulgin Research Institute (ASRI), and acquired Beckley Psytech's ophthalmology program, targeting psychiatry, neurodegeneration, and retinal degeneration.
Drug Pipeline
2Ophthalmology Neuroplastogen Program (ex-Beckley Psytech)
Neuroplastogen candidates targeting retinal degeneration, acquired from Beckley Psytech. Exploring 5-HT2A receptor modulation for age-related retinal conditions.
ASRI Neuroplastogen Pipeline
Novel non-hallucinogenic neuroplastogens derived from Shulgin compound library, developed in collaboration with Hadassah Brain Labs for psychiatric and neurological indications.
Quick Facts
- Type
- Private Biotech
- Founded
- 2022
- Lead Stage
- Pre-clinical
- Website
- Visit